Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, the Immunological Impact, and the Effect on HIV Ex-Vivo Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis.
Leal L, Guardo AC, Bedoya LM, Rodríguez de Miguel C, Climent N, Rovira C, Beltrán M, Llach J, Alcamí J, Kashuba ADM, Gatell JM, Plana M, García F. Leal L, et al. Among authors: guardo ac. AIDS Res Hum Retroviruses. 2023 May;39(5):211-221. doi: 10.1089/AID.2021.0232. Epub 2023 Feb 15. AIDS Res Hum Retroviruses. 2023. PMID: 36416229 Free PMC article.
Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation.
Torres B, Guardo AC, Leal L, Leon A, Lucero C, Alvarez-Martinez MJ, Martinez MJ, Vila J, Martínez-Rebollar M, González-Cordón A, Gatell JM, Plana M, García F. Torres B, et al. Among authors: guardo ac. J Int AIDS Soc. 2014 Sep 29;17(1):19246. doi: 10.7448/IAS.17.1.19246. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25280865 Free PMC article.
A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.
Rojas J, Blanco JL, Sanchez-Palomino S, Marcos MA, Guardo AC, Gonzalez-Cordon A, Lonca M, Tricas A, Rodriguez A, Romero A, Miro JM, Mallolas J, Gatell JM, Plana M, Martinez E. Rojas J, et al. Among authors: guardo ac. AIDS. 2018 Jul 31;32(12):1633-1641. doi: 10.1097/QAD.0000000000001843. AIDS. 2018. PMID: 29746294 Clinical Trial.
Immunological and virological findings in a patient with exceptional post-treatment control: a case report.
Climent N, Ambrosioni J, González T, Xufré C, Casadellà M, Noguera-Julian M, Paredes R, Plana M, Grau-Expósito J, Mallolas J, Alcamí J, Sánchez-Palomino S, Miró JM; Hospital Clínic de Barcelona PHI investigators. Climent N, et al. Lancet HIV. 2023 Jan;10(1):e42-e51. doi: 10.1016/S2352-3018(22)00302-2. Epub 2022 Oct 27. Lancet HIV. 2023. PMID: 36354046
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M. García F, et al. Among authors: guardo ac. Vaccine. 2011 Oct 26;29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098. Epub 2011 Sep 9. Vaccine. 2011. PMID: 21907749 Clinical Trial.
In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.
Arberas H, Guardo AC, Bargalló ME, Maleno MJ, Calvo M, Blanco JL, García F, Gatell JM, Plana M. Arberas H, et al. Among authors: guardo ac. J Antimicrob Chemother. 2013 Mar;68(3):577-86. doi: 10.1093/jac/dks432. Epub 2012 Nov 14. J Antimicrob Chemother. 2013. PMID: 23152485
34 results